Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595784 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2GAAMAPK1KMT2ATRPV4 | |
| SCHEMBL30540030 | 0.85 | TRPV4 (0.47) | SMN1; SMN2GAAMAPK1KMT2ATRPV4 | |
| SCHEMBL1817484 | 0.85 | TRPV4 (0.47) | SMN1; SMN2GAAMAPK1KMT2ATRPV4 | |
| SCHEMBL5102193 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2GAAMAPK1KMT2AALDH1A1 | |
| Methane SCHEMBL5110536 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2GAAMAPK1KMT2AALDH1A1 | |
| SCHEMBL28145710 | 0.81 | CA2 (0.49) | SMN1; SMN2GAAMAPK1KMT2AALDH1A1 | |
| SCHEMBL938215 | 0.81 | HPGD (0.55) | GAAMAPK1KMT2AALDH1A1MAPT | |
| SCHEMBL27699833 | 0.81 | SOS1 (0.47) | SMN1; SMN2GAAMAPK1KMT2AALDH1A1 | |
| SCHEMBL24429415 | 0.81 | KAT6A (0.47) | TRPV4ALDH1A1KAT6ANPSR1 | |
| Hydrochloric Acid SCHEMBL28128421 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2GAAMAPK1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964540-A | Deuterated pyrrole sulfonyl derivative, and preparation method and application thereof | 天地恒一制药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| CN-114507163-A | Method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride | 尚科生物医药（上海）有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-109311894-A | N- (substituted-phenyl) -sulfonamide derivatives as kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-10059713-B2 | 3-substituted 2-amino-indole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-28 | — | — | US | disclosed |
| EP-2758399-B1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-11-15 | — | — | EP | disclosed |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA CAMBRIDGE LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| CN-106488919-A | 3-substituted 2-aminoindole derivatives | 武田药品工业株式会社 | 2017-03-08 | — | — | CN | disclosed |
| CN-103012407-B | N-[4-(1H-pyrazolo [3,4-b] pyrazine-6-base)-phenyl]-sulfonamides and the purposes as medicine thereof | 赛诺菲 | 2016-06-29 | — | — | CN | disclosed |
| US-20160175304-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-06-23 | — | — | US | disclosed |
| US-9221828-B2 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides as pharmaceuticals | SANOFI (FR) | 2015-12-29 | — | — | US | disclosed |
| US-9174993-B2 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2015-11-03 | — | — | US | disclosed |
| EP-2570415-B1 | N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI SA (FR) | 2015-08-26 | — | — | EP | disclosed |
| US-20140357640-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140288083-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-09-25 | — | — | US | disclosed |
| EP-2758399-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013041119-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041502-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-28 | — | — | WO | disclosed |
| US-20130072493-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| EP-2570415-A1 | N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2013-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072493-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | SMN1; SMN2 1879/4885GAA 4127/4885MAPK1 148/4885 |
| US-10059713-B2 | 3-substituted 2-amino-indole derivatives | NPY5R, XDH, NPY4R | SMN1; SMN2 3544/4885GAA 3619/4885MAPK1 4336/4885 |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | XBP1, ERN1, ERN2 | SMN1; SMN2 193/4885GAA 1664/4885MAPK1 544/4885 |
| US-20160175304-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | SMN1; SMN2 1879/4885GAA 4127/4885MAPK1 148/4885 |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | NPY5R, XDH, NPY4R | SMN1; SMN2 3544/4885GAA 3619/4885MAPK1 4336/4885 |
| US-20140357640-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK3, SGK1, SGK2 | SMN1; SMN2 1863/4885GAA 4068/4885MAPK1 169/4885 |
| US-20140288083-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | SMN1; SMN2 1879/4885GAA 4127/4885MAPK1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.